Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroids in Severe Alcoholic Hepatitis with Early Improvement
NCT03160651Unknown
- Sponsor
- Erasmus Hospital
- Start
- Feb 2018
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial in alcoholic hepatitis (AH) comparing Methylprednisolone with Placebo (2 arms). Primary endpoint: Mortality at 90 days. Status: unknown.
02
Drugs
methylprednisolone
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03160651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160651.